Novartis Korea May Face Business Suspension In Rebate Probe
Novartis’ South Korean subsidiary could face a business suspension and other administrative measures after prosecutors indicted several employees without detention on charges of illegal rebate payments.
You may also be interested in...
In an unprecedented move to eliminate rebates in the pharma industry, South Korean pharma firms have conducted an anonymous survey to identify firms suspected of being involved in the practice in return for prescriptions.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.